Research

Application follows successful pre-clinical animal studies at the University of Arkansas

Growing scope of medicinal applications for CBD is a key driver of the anticipated market growth

The improvements were sustained for at least one month after the experiment

Monitoring the Future panel study supported by the NIH outlines new statistics

New fund will support studies on psychedelic-assisted therapies for the treatment of mental health conditions

Flagship product from company's medical cannabis division now set for clinical trial use

Biotechnology organization will also supply LaNeo product to Australian research institute for clinical trial

New research estimates that over 5.5 million American adults used psychoactive substances in 2019

Better follow up is also a necessity, and wearable sleep trackers are only the beginning

New statistics come from over 200,000 unique experiences cannabis users have recorded on the company platform

The partnership started in 2018

Vancouver producer to supply synthetic psychedelic compounds to designated investigators and companies

Innovative new studies in the Middle East receive approval from Israeli Ministry of Health

Canadian biopharmaceutical company will receive government tax incentive for studies down under

Market anticipated to ascend in value by 250% into 2031

Multi-disciplinary controlled substance company set to commence operations at Calgary facility

Upcoming event said to feature powerful female speakers from broad cross-section of practices and expertise

Lead investigators receive US$16M grant to support new research endeavour

New Hampshire engineering students undertake innovative research pertinent to cannabis industry

New inhalable drug containing CBD designed for efficacious treatment of brain injuries

Award-winning documentary sequel to be followed by Q&A with renowned psychedelic community figures

New survey outlines that Texans prefer cannainoid treatment for chronic pain over opioids

Researchers also found studies saw a reduction of serotonin following antidepressant use

Initial dose of FT-104 given in Adelaide, company announces name change

Canadian company continues to develop its presence in the clinical psychedelic sector

International cannabis concentrate sector anticipated to triple in value by 2030

Psychedelic Fundamentals course to provide broad overview of a vast topic

Flexible new curriculum designed to help students into cannabis career paths

FDA-approved psilocin study in California said to be first of its kind for industry

Married couple now run state-of-the-art laboratory in Las Vegas dedicated to advancing new therapies

Canadian life sciences outfit continues to push the envelope in the clinical psychedelic sector

Company stock portfolio appreciates significantly since January 2021

Christie's helps psychedelic research group generate unprecedented revenue via crypto-asset art auction

Company announces development of novel intranasal formulation with promising efficacy

Patient enlistment for new study to treat Major Depressive Disorder set to begin promptly

B.C. Mental health care company develops passion inspired by Utah pioneers

Biotechnology outfit set to receive attention on American TV this summer

Company isolates 4-PO-Psilocin into biologically active salt with 99% purity ratio

New academic journal spotlights potential for rare cannabinoids to treat skin conditions

Dimethyltryptamine continues to demonstrate tremendous therapeutic potential